Unspecified Childhood Solid Tumor, Protocol Specific Clinical Trial
Official title:
A Phase II Study of Intrathecal Topotecan (NSC #609699) in Patients With Refractory Meningeal Malignancies
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. This phase II trial is studying how well topotecan hydrochloride works in treating children with meningeal cancer that has not responded to previous treatment
Status | Completed |
Enrollment | 77 |
Est. completion date | February 2009 |
Est. primary completion date | April 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 1 Year to 21 Years |
Eligibility |
Inclusion Criteria: - Histologically proven refractory leukemia, lymphoma, or other solid tumor thathas overt meningeal involvement (Recurrent CNS acute lymphoblastic leukemia stratum only open to accrual as of 11/30/04) - Definition of meningeal disease: - Leukemia/lymphoma (including acute lymphoblastic leukemia) - CSF cell count greater than 5/mm^3 AND evidence of blast cells oncytospin preparation or by cytology - Refractory to conventional therapy, including radiotherapy (i.e., in second or greater relapse) - No concurrent bone marrow relapse - Solid tumors (including medulloblastoma) - Presence of tumor cells on cytospin preparation or cytology OR presence ofmeningeal disease on MRI scans - No clinical evidence of obstructive hydrocephalus or compartmentalization ofCSF flow as documented by radioisotope indium In 111 or technetium Tc 99 DTPAflow study - If CSF flow block is demonstrated, focal radiotherapy must be administered tosite of block to restore flow and a repeat CSF flow study must show clearing of blockage - No ventriculoperitoneal or ventriculoatrial shunt unless: - Patient is shunt independent and there is evidence that the shunt is nonfunctional - CSF flow study demonstrates normal flow - No impending cord compression, CNS involvement requiring local radiotherapy(e.g., optic nerve), or isolated bulky ventricular or leptomeningeal basedlesions - Performance status - Lansky 50-100% (age 10 and under) - Performance status - Karnofsky 50-100% (over age 10) - At least 8 weeks - Platelet count greater than 40,000/mm^3 (transfusions allowed) - Bilirubin less than 2.0 mg/dL - SGPT less than 5 times normal - Creatinine less than 1.5 mg/dL - Electrolytes, calcium, and phosphorus normal - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No significant illness (e.g., uncontrolled infection, except HIV [i.e., AIDS-related lymphomatous meningitis]) - Prior immunotherapy allowed and recovered - At least 3 weeks since systemic CNS directed chemotherapy (6 weeks for nitrosoureas) and recovered - At least 1 week since prior intrathecal (IT) chemotherapy (2 weeks for cytarabine [liposomal]) - No prior IT chemotherapy on days -14 to -7 before study entry unless evidence of disease progression (e.g., increasing WBC and percentage blasts in patients with leukemia/lymphoma or increased leptomeningeal enhancements in patients with solid tumors) (Recurrent CNS acute lymphoblastic leukemia stratum only open to accrual as of 11/30/04) - Concurrent chemotherapy to control systemic disease or bulk CNS disease allowed if the systemic chemotherapy is not a phase I study agent that significantly penetrates the CSF (e.g., high-dose systemic methotrexate [greater than 1 g/m^2], thiotepa, high-dose cytarabine, temozolomide, IV mercaptopurine, nitrosourea, or topotecan) or an agent known to have serious unpredictable CNS side effects - Concurrent dexamethasone or prednisone allowed if part of a systemic chemotherapy regimen - See Disease Characteristics - At least 8 weeks since prior cranial irradiation and recovered - No concurrent whole brain or craniospinal irradiation - At least 7 days since prior investigational drug - Time period should be extended if patient has received any investigational agent that is known to have delayed toxic effects after 7 days or a prolonged half-life - No other concurrent investigational agents - No concurrent therapy (IT or systemic) for leptomeningeal disease - No other concurrent systemic agents that significantly penetrate the blood-brain barrier |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Children's Oncology Group | Arcadia | California |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | For the leukemia and lymphoma patients, an objective response rate, defined to be the proportion of Complete Responses of less than 0.10 | Up to 54 months | No | |
Primary | For the patients with solid tumors, a proportion of patients who do not experience an event, defined to be death, progressive disease, relapse, or second malignancy of less than 0.3 | Up to 54 months | No | |
Primary | Safety and toxicity | Up to 54 months | Yes | |
Primary | Concentration of matrix metalloproteinases in the CSF | Up to 54 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01164163 -
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
|
Phase 1 | |
Completed |
NCT00985868 -
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors
|
Phase 1 | |
Terminated |
NCT00949117 -
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
|
Phase 2 | |
Completed |
NCT00253474 -
PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma
|
Phase 1 | |
Completed |
NCT00281944 -
Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00084695 -
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
|
Phase 2 | |
Completed |
NCT00053963 -
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
|
Phase 1 | |
Completed |
NCT00003070 -
Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
|
Phase 3 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003754 -
Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers
|
Phase 2 | |
Completed |
NCT00016861 -
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors
|
Phase 1 | |
Completed |
NCT00004005 -
Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
|
Phase 2 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Recruiting |
NCT00898794 -
Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer
|
N/A | |
Terminated |
NCT00429702 -
Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy
|
Phase 2 | |
Completed |
NCT00459238 -
Telephone-Based Cancer Education With or Without Telephone-Based Counseling in Young Participants
|
N/A | |
Completed |
NCT00387920 -
Sunitinib in Treating Young Patients With Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT00138216 -
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT00070473 -
Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors
|
Phase 1 |